Citations

Showing 10 of 108104 citations.

Awareness, Perceptions, and Literacy Surrounding Hearing Loss and Hearing Rehabilitation Among the Adult Population in the United States
Carlson, Matthew L. , Nassiri, Ashley M. , Marinelli, John P. , Lohse, Christine M. , Sydlowski, Sarah

Mayo Clinic

Otology & Neurotology | January 21, 2022 | Volume: 43 | Issue: 3 | Pages: e323-e330

10.1097/mao.0000000000003473 | PMID 35061637 Get It

Objective: To characterize current awareness, perceptions, and literacy surrounding hearing loss among the adult population in the United States. Study Design: National cross-sectional survey study. Setting: United States. Patients: Adults between 50 and 80 years of age in the United States. Results: Survey respondents included 1,250 adults between the ages of 50 and 80 years, including 500 who indicated at least moderate hearing loss and were using hearing aids and 750 who denied having hearing loss and were not using hearing aids. Only 9% of patients were able to correctly identify what constitutes a “normal” or “average” range for hearing. By comparison, a “normal” range of values for vision, blood pressure, and total cholesterol were identified correctly by 93%, 85%, and 52% of the 1,250 surveyed adults, respectively. When asked to rank the importance of addressing hearing loss within the context of 10 other common health conditions, hearing loss was ranked third to least important. When considering annual health maintenance, respondents indicated they were “very likely” to have an annual physical exam (72%), a cholesterol test (70%), an eye exam (66%), and bring their pet to a veterinarian (59%) over twice as frequently as having their hearing evaluated (27%). When evaluating awareness surrounding associations between hearing loss and other health and social issues, less than one-fourth indicated strong awareness about links between hearing loss and depression, employability and income, fall risk, dementia, and type 2 diabetes. While most patients acknowledge the potential impacts of hearing loss on safety, quality of life, and health, less than half believe that hearing loss is treatable and less than 20% believe that hearing loss is preventable. Conclusion: Despite widespread literacy of what constitutes normal vision, blood pressure, and total cholesterol levels, respondents exhibit substantially poorer understanding of “normal” hearing levels. Most adults believe that few treatment options exist for the management of hearing loss. Underlying the uniformly limited literacy surrounding hearing loss and its treatment options is the adult population's lack of appreciation for the long-term health sequelae of untreated hearing loss.
Spectrum of MRI Features of Mucin-producing Neoplasms in the Abdomen and Pelvis
Wei, Pei-Kang , Gupta, Mamta , Tsai, Leo L. , Lee, Karen , Jaramillo, Adrian M. , Smith, Martin P. , LeGout, Jordan D. , Shenoy‐Bhangle, Anuradha S. , Lee, Karen S

Mayo Clinic

RadioGraphics | January 21, 2022 | Volume: 42 | Issue: 2 | Pages: 469-486

10.1148/rg.210055 | PMID 35061517 Get It

Pre-Anesthetic Medical Evaluations: Criteria Considerations for Telemedicine Alternatives to Face to Face Visits
Khera, Kushal D. , Blessman, Joseph D., Deyo-Svendsen, Mark , Angstman, Kurt B. , Deyo-Svendsen, Mark E , Blessman, Joseph D., Miller, Nathaniel E.

Mayo Clinic

Health Services Research and Managerial Epidemiology | January 21, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23333928221074895 | PMID 35083372 Get It

Background The number of pre-anesthetic medical evaluations (PAMEs) being conducted in primary care is increasing. Due to the COVID-19 pandemic, the use of telemedicine has surged, providing a feasible way to conduct some of these visits. This study aimed to identify patient-related factors where a face to face (FTF) evaluation is indicated, measured by the need for pre-operative testing. Methods A retrospective chart review was conducted on patients age ≥ 18 years who had a PAME between January 2019–June 2020 at a rural primary care clinic in Southeast Minnesota. Data collected included age, gender, Charlson Comorbidity Index Score, medications, revised cardiac risk index (RCRI), smoking status, exercise capacity, body mass index, and pre-operative testing. Logistical regression modeling for odds ratios of outcomes was performed. Results 254 patients were included, with an average age of 64.1 years; 43.7% were female. Most were obese (mean BMI 31.6), non-smoking (93.7%) with excellent functional capacity (87.8% ≥ 5 METs). 76.8% of the planned surgeries were intermediate or high risk. 35.0% ( n = 89) of visits resulted in medication adjustments and 76.7% ( n = 195) in pre-operative testing. Age ≥ 65 years, ≥7 current medications, and diabetes all significantly increased the odds of requiring pre-operative testing ( P < .05). Conclusions This study was able to identify patient-related factors that increased the likelihood of requiring pre-operative testing. Patients who are age ≥ 65 years, ≥7 current medications, and those with diabetes could be scheduled for a FTF evaluation. Others could be scheduled for a telemedicine visit to minimize health-care exposures.
Prognostic and Treatment Differences Between T1a and T1b Glottic Cancer
Syal, Amit , Zhang, Nan , Karle, William E. , Lott, David G , Zhang, Nan , Karle, William E , Lott, David G.

Mayo Clinic

The Laryngoscope | January 21, 2022 | Volume: 132 | Issue: 11 | Pages: 2187-2193

10.1002/lary.30030 | PMID 35060629 Get It

ObjectivesThis study was designed to evaluate significant differences in treatment and survival outcomes between patients with T1a and T1b glottic cancer.MethodsPatients within the SEER Research Plus, 18 Registries dataset who were diagnosed with Stage I T1a or T1b cancer of the glottis between 2004 and 2015 were included in this study. Data prior to 2004 could not be included, as the SEER database did not distinguish between T1a and T1b glottic cancer until that year.ResultsThe 5‐year disease‐specific survival for T1a patients was significantly better than that of patients diagnosed with T1b glottic cancer. Age and year of diagnosis were also independent factors that impacted mortality. More patients who were diagnosed with T1b glottic cancer underwent external beam radiation than those diagnosed with T1a glottic cancer.ConclusionOur data shows that there are several independent factors effecting mortality including T classification, age at time of diagnosis, and year of diagnosis. T1a glottic cancers also show a significantly better prognosis compared with T1b. T1b glottic cancers are much more likely to be treated with primary radiotherapy compared with surgery.Level of Evidence4 Laryngoscope, 132:2187–2193, 2022
Internet-based platform for a low-calorie dietary intervention involving prepackaged food for weight loss in overweight and obese individuals in China: protocol for a randomised controlled trial
Wang, Suyuan , Zhang, Chenghui , Zhong, Lingyu, Lerman, Lilach O. , Lerman, Amir , Guo, Yanhong , Wu, Yunhong , Wang, Suyuan , Lerman, Lilach O , Lerman, Amir , Wang, Xi , Zhong, Lingyu, López-Jiménez, Francisco

Mayo Clinic

BMJ Open | January 21, 2022 | Volume: 12 | Issue: 1 | Pages: e048106

10.1136/bmjopen-2020-048106 | PMID 35063952 Get It

Introduction Obesity is a global health issue that impacts quality of life. A calorie-restricted diet with high-intensity consultation provided via the internet may be an effective way to lose weight. The objective of this study was to assess the effectiveness of a practitioner-guided, mobile internet-based low-energy dietary intervention in overweight and obese populations in China. Methods and analysis This open-label randomised controlled trial enrolled 220 overweight and obese adults aged 18–70 years who met the inclusion criteria. Participants were assigned to the control group (n=110) or trial group (n=110). The trial group will be enrolled in the MetaWell programme, a weight loss programme using diet replacement products, wireless scales and a mobile phone app. Participants in the control group will receive paper material containing a sample diet for weight loss. The follow-up period will be 1 year, and measurements will occur at 3, 6 and 12 months. Dual-emission X-ray absorptiometry and abdominal quantitative CT will be performed to estimate the percentage of overall body fat and areas of visceral and subcutaneous fat, alongside several cardiometabolic measurements. The primary outcome of this study is the change in body mas index (BMI) at 6 months after enrolment. A mixed-effects model will be used to compare BMI and body fat changes between the two groups. Ethics and dissemination This study was approved by the ethics committee of the Hospital of Chengdu Office of the People’s Government of the Tibetan Autonomous Region. Advertisements for recruitment will be sent via official accounts using WeChat. The results will be disseminated via publications in academic journals and our clinic. Our study group will maintain contact with the participants to inform them of the study findings. Trial registration number ChiCTR1900021630.
Equivalent Cellular and Humoral Immunity to Varicella Zoster Virus in Patients With Inflammatory Bowel Disease and Healthy Older Adults for Whom Immunization Is Recommended
Caldera, Freddy , Wald, Arnold , Saha, Sumona , McCrone, Sue, Caldera, Freddy , Smith, Ryan C. , Farraye, Francis A. , Hayney, Mary S.

Mayo Clinic

Clinical and Translational Gastroenterology | January 21, 2022 | Volume: 13 | Issue: 1 | Pages: e00446

10.14309/ctg.0000000000000446 | PMID 35060934 Get It

INTRODUCTION: Patients with inflammatory bowel disease (IBD) are at an increased risk of herpes zoster (HZ). HZ is caused by reactivation of the varicella zoster virus (VZV) and is prevented by strong VZV-specific cell-mediated immunity. The aim of our study was to evaluate whether patients with IBD had lower or equivalent protection compared with healthy controls (HCs) at age 50 years and older. METHODS: We performed a cross-sectional study at a single academic center and evaluated cellular and humoral immunity to VZV in patients with IBD at age 35–49 years vs HCs aged 50–59 years. All patients with IBD were on stable medication regimens for at least 3 months. VZV-specific cell-mediated immunity was measured via ELISPOT, and humoral immunity was measured via a quantitative VZV antibody enzyme-linked immunosorbent assay assay. RESULTS: Seventy-seven patients with IBD and 12 HCs were enrolled in the study. There was no significant difference in ELISPOT counts between patients with IBD and HCs ( P = 0.54). In addition, there was also no significant difference between ELISPOT counts in immunosuppressed patients with IBD (N = 45) and HCs ( P = 0.32). We also found no correlations between ELISPOT counts and age (Spearman rho 0.014; P = 0.90). Patients with IBD had similar IgG VZV antibody levels (median 19 mIU/mL; range 0.5–218) compared with HCs (median 23.5 mIU/mL (range 4–34); P = 0.54). DISCUSSION: Young patients with IBD have equivalent cellular and humoral immunity to VZV as healthy older adults in whom HZ immunization is recommended.
RBE‐weighted dose and its impact on the risk of acute coronary event for breast cancer patients treated with intensity modulated proton therapy
Liu, Chunbo , Bradley, Julie A. , Beltran, Chris , Beltran, Chris J., Beltran, Chris J , Zheng, Dandan , Vega, Raymond B. Mailhot , Mendenhall, Nancy P. , Liang, Xiaoying

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 21, 2022 | Volume: 23 | Issue: 4 | Pages: No page available

10.1002/acm2.13527 | PMID 35060317 Get It

AbstractPurposeTo evaluate the relative biological effectiveness (RBE)‐weighted dose to the heart and to estimate RBE uncertainties when assuming a constant RBE of 1.1, for breast cancer patients receiving intensity‐modulated proton therapy (IMPT). Further, to study the impact of RBE uncertainties on the risk of an acute coronary event (ACE).Material and methodsWe analyzed 20 patients who received IMPT to either the left breast (n = 10) or left chest wall (n = 10) and regional lymph nodes. The Monte Carlo simulation engine, MCsquare, was used to simulate the dose‐averaged linear energy transfer (LETd) map. The RBE‐weighted dose to the heart and its substructures was calculated using three different RBE models. The risk of ACE was estimated per its linear relationship with mean heart dose (MHD) as established by Darby et al.ResultsThe median MHD increased from 1.33 GyRBE assuming an RBE of 1.1 to 1.64, 1.87, and 1.99 GyRBE when using the RBE‐weighted dose models. The median values (and ranges) of the excess absolute risk of ACE were 0.4% (0.1%–0.8%) when assuming an RBE of 1.1, and 0.6% (0.2%–1.0%), 0.6% (0.2%–1.1%), and 0.7% (0.2%–1.1%) with the RBE‐weighted models. For our patient cohort, the maximum excess absolute risk of ACE increased by 0.3% with the RBE‐weighted doses compared to the constant RBE of 1.1, reaching an excess absolute ACE risk of 1.1%. The interpatient LETd variation was small for the relevant high‐dose regions of the heart.ConclusionAll three RBE models predicted a higher biological dose compared to the clinical standard dose assuming a constant RBE of 1.1. An underestimation of the biological dose results in underestimation of the ACE risk. Analyzing the voxel‐by‐voxel biological dose and the LET map alongside clinical outcomes is warranted in the development of a more accurate normal‐tissue complication probability model.
Minnesota Electronic Health Record Consortium COVID-19 Project: Informing Pandemic Response Through Statewide Collaboration Using Observational Data
Waring, Stephen C. , Bodurtha, Peter , Khazanchi, Rohan , Gildemeister, Stefan, Mink, Pamela J. , DeSilva, Malini B. , Murray, Anne M. , Rai, Nayanjot, Sonier, Julie, Neely, Claire , Johnson, Steve , McFarling, Lynn, Dudley, R. Adams , Drawz, Paul E. , Winkelman, Tyler N A , Johnson, Steven G. , Waring, Stephen C. , Drawz, Paul , Margolis, Karen L. , Rai, Nayanjot, Chamberlain, Alanna M. , Yu, Yue

Mayo Clinic

Public Health Reports® | January 21, 2022 | Volume: 137 | Issue: 2 | Pages: 263-271

10.1177/00333549211061317 | PMID 35060411 Get It

Objective: Robust disease and syndromic surveillance tools are underdeveloped in the United States, as evidenced by limitations and heterogeneity in sociodemographic data collection throughout the COVID-19 pandemic. To monitor the COVID-19 pandemic in Minnesota, we developed a federated data network in March 2020 using electronic health record (EHR) data from 8 multispecialty health systems. Materials and Methods: In this serial cross-sectional study, we examined patients of all ages who received a COVID-19 polymerase chain reaction test, had symptoms of a viral illness, or received an influenza test from January 3, 2016, through November 7, 2020. We evaluated COVID-19 testing rates among patients with symptoms of viral illness and percentage positivity among all patients tested, in aggregate and by zip code. We stratified results by patient and area-level characteristics. Results: Cumulative COVID-19 positivity rates were similar for people aged 12-64 years (range, 15.1%-17.6%) but lower for adults aged ≥65 years (range, 9.3%-10.7%). We found notable racial and ethnic disparities in positivity rates early in the pandemic, whereas COVID-19 positivity was similarly elevated across most racial and ethnic groups by the end of 2020. Positivity rates remained substantially higher among Hispanic patients compared with other racial and ethnic groups throughout the study period. We found similar trends across area-level income and rurality, with disparities early in the pandemic converging over time. Practice Implications: We rapidly developed a distributed data network across Minnesota to monitor the COVID-19 pandemic. Our findings highlight the utility of using EHR data to monitor the current pandemic as well as future public health priorities. Building partnerships with public health agencies can help ensure data streams are flexible and tailored to meet the changing needs of decision makers.
Surgical approaches to refractory central lobule epilepsy: a systematic review on the role of resection, ablation, and stimulation in the contemporary era
Kerezoudis, Panagiotis , Meyer, Fredric B. , Lundstrom, Brian N. , Worrell, Gregory A. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | January 21, 2022 | Volume: 137 | Issue: 3 | Pages: 735-746

10.3171/2021.10.jns211875 | PMID 35171813 Get It

OBJECTIVE Epilepsy originating from the central lobule (i.e., the primary sensorimotor cortex) is a challenging entity to treat given its involvement of eloquent cortex. The objective of this study was to review available evidence on treatment options for central lobule epilepsy. METHODS A comprehensive literature search (PubMed/Medline, EMBASE, and Scopus) was conducted for studies (1990 to date) investigating postoperative outcomes for central lobule epilepsy. The primary and secondary endpoints were seizure freedom at last follow-up and postoperative neurological deficit, respectively. The following procedures were included: open resection, multiple subpial transections (MSTs), laser and radiofrequency ablation, deep brain stimulation (DBS), responsive neurostimulation (RNS), and continuous subthreshold cortical stimulation (CSCS). RESULTS A total of 52 studies and 504 patients were analyzed. Most evidence was based on open resection, yielding a total of 400 patients (24 studies), of whom 62% achieved seizure freedom at a mean follow-up of 48 months. A new or worsened motor deficit occurred in 44% (permanent in 19%). Forty-six patients underwent MSTs, of whom 16% achieved seizure freedom and 30% had a neurological deficit (permanent in 12%). There were 6 laser ablation cases (cavernomas in 50%) with seizure freedom in 4 patients and 1 patient with temporary motor deficit. There were 5 radiofrequency ablation cases, with 1 patient achieving seizure freedom, 2 patients each with Engel class III and IV outcomes, and 2 patients with motor deficit. The mean seizure frequency reduction at the last follow-up was 79% for RNS (28 patients), 90% for CSCS (15 patients), and 73% for DBS (4 patients). There were no cases of temporary or permanent neurological deficit in the CSCS or DBS group. CONCLUSIONS This review highlights the safety and efficacy profile of resection, ablation, and stimulation for refractory central lobe epilepsy. Resection of localized regions of epilepsy onset zones results in good rates of seizure freedom (62%); however, nearly 20% of patients had permanent motor deficits. The authors hope that this review will be useful to providers and patients when tailoring decision-making for this intricate pathology.
Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry
Alvi, Mohammed Ali, Asher, Anthony L., Michalopoulos, Giorgos D., Grills, Inga S., Warnick, Ronald E., McInerney, James, Chiang, Veronica L., Attia, Albert, Timmerman, Robert, Chang, Eric, Kavanagh, Brian D., Andrews, David W., Walter, Kevin, Bydon, Mohamad, Sheehan, Jason P., Warnick, Ronald E. , Alvi, Mohammed Ali , Michalopoulos, Giorgos D. , Alvi, Mohammed Ali , Michalopoulos, Giorgos , Alvi, Mohammed Ali, Asher, Anthony L., Grills, Inga S., Warnick, Ronald E., McInerney, James, Chiang, Veronica L., Attia, Albert, Timmerman, Robert, Chang, Eric, Kavanagh, Brian D., Andrews, David W., Walter, Kevin, Bydon, Mohamad, Sheehan, Jason P.

Mayo Clinic

Journal of Neurosurgery | January 21, 2022 | Volume: 137 | Issue: 4 | Pages: 985-998

10.3171/2021.10.jns211410 | PMID 35171833 Get It

OBJECTIVE Stereotactic radiosurgery (SRS) has been increasingly employed in recent years to treat intracranial metastatic lesions. However, there is still a need for optimization of treatment paradigms to provide better local control and prevent progressive intracranial disease. In the current study, the authors utilized a national collaborative registry to investigate the outcomes of patients with intracranial metastatic disease who underwent SRS and to determine factors associated with lesion treatment response, overall progression, and mortality. METHODS The NeuroPoint Alliance SRS registry was queried for all patients with intracranial metastatic lesions undergoing single- or multifraction SRS at participating institutions between 2016 and 2020. The main outcomes of interest included lesion response (lesion-level analysis), progression using Response Assessment for Neuro-Oncology criteria, and mortality (patient-level analysis). Kaplan-Meier analysis was used to report time to progression and overall survival, and multivariable Cox proportional hazards analysis was used to investigate factors associated with lesion response, progression, and mortality. RESULTS A total of 501 patients (1447 intracranial metastatic lesions) who underwent SRS and had available follow-up were included in the current analyses. The most common primary tumor was lung cancer (49.5%, n = 248), followed by breast (15.4%, n = 77) and melanoma (12.2%, n = 61). Most patients had a single lesion (44.9%, n = 225), 29.3% (n = 147) had 2 or 3 lesions, and 25.7% (n = 129) had > 3 lesions. The mean sum of baseline measurements of the lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) was 35.54 mm (SD 25.94). At follow-up, 671 lesions (46.4%) had a complete response, 631 (43.6%) had a partial response (≥ 30% decrease in longest diameter) or were stable (< 30% decrease but < 20% increase), and 145 (10%) showed progression (> 20% increase in longest diameter). On multivariable Cox proportional hazards analysis, melanoma-associated lesions (HR 0.48, 95% CI 0.34–0.67; p < 0.001) and larger lesion size (HR 0.94, 95% CI 0.93–0.96; p < 0.001) showed lower odds of lesion regression, while a higher biologically effective dose was associated with higher odds (HR 1.001, 95% CI 1.0001–1.00023; p < 0.001). A total of 237 patients (47.3%) had overall progression (local failure or intracranial progressive disease), with a median time to progression of 10.03 months after the index SRS. Factors found to be associated with increased hazards of progression included male sex (HR 1.48, 95% CI 1.108–1.99; p = 0.008), while administration of immunotherapy (before or after SRS) was found to be associated with lower hazards of overall progression (HR 0.62, 95% CI 0.460–0.85; p = 0.003). A total of 121 patients (23.95%) died during the follow-up period, with a median survival of 19.4 months from the time of initial SRS. A higher recursive partitioning analysis score (HR 21.3485, 95% CI 1.53202–3.6285; p < 0.001) was found to be associated with higher hazards of mortality, while single-fraction treatment compared with hypofractionated treatment (HR 0.082, 95% CI 0.011–0.61; p = 0.015), administration of immunotherapy (HR 0.385, 95% CI 0.233–0.64; p < 0.001), and presence of single compared with > 3 lesions (HR 0.427, 95% CI 0.187–0.98; p = 0.044) were found to be associated with lower risk of mortality. CONCLUSIONS The comparability of results between this study and those of previously published clinical trials affirms the value of multicenter databases with real-world data collected without predetermined research purpose.